Raso V, Brown M, McGrath J
Boston Biomedical Research Institute, Boston, Massachusetts 02114, USA.
J Biol Chem. 1997 Oct 31;272(44):27623-8. doi: 10.1074/jbc.272.44.27623.
Bispecific antibodies were designed to deliver a reversibly bound ligand into target cells and then spontaneously release it upon passage into acidified vesicles. These reagents were assembled by coupling monoclonal antibodies that recognize acid-sensitive epitopes on diphtheria toxin to cell type-specific monoclonal antibodies. The dual binding capacity of the bispecific antibodies was confirmed by delivery of 125I-diphtheria toxin to target molecules present on intact cells. Bispecific antibodies directed against transferrin receptors on human cells were loaded with toxin and tested for cytotoxicity. The mutant diphtheria toxins CRM107 and CRM45 were used since their inability to bind cell receptors renders them ordinarily nontoxic. Their full cytotoxic potential, however, was restored via bispecific antibody-mediated delivery and release within low pH intracellular vesicles. Cytotoxicity was shown to be specific by blocking receptor sites and to be acidification-dependent by protection using NH4Cl to raise endosomal pH. Kinetics for inhibition of cellular protein synthesis was identical for native diphtheria toxin and the bispecific antibody. CRM107 combination. The rate of inhibition (t1/2 = 20 min) indicated that release of CRM107 from the antibody combining site was fast, and its toxic action was unimpeded by this delivery mechanism.
双特异性抗体被设计用于将可逆结合的配体递送至靶细胞,然后在进入酸化囊泡时自发释放。这些试剂是通过将识别白喉毒素上酸敏表位的单克隆抗体与细胞类型特异性单克隆抗体偶联而组装的。通过将125I-白喉毒素递送至完整细胞上存在的靶分子,证实了双特异性抗体的双重结合能力。针对人细胞上转铁蛋白受体的双特异性抗体加载毒素并测试其细胞毒性。使用突变型白喉毒素CRM107和CRM45,因为它们无法结合细胞受体,通常无毒。然而,它们的全部细胞毒性潜能通过双特异性抗体介导的递送和在低pH细胞内囊泡中的释放得以恢复。通过阻断受体位点显示细胞毒性具有特异性,通过使用NH4Cl提高内体pH进行保护显示细胞毒性依赖于酸化。天然白喉毒素和双特异性抗体- CRM107组合对细胞蛋白质合成的抑制动力学相同。抑制速率(t1/2 = 20分钟)表明CRM107从抗体结合位点的释放很快,并且其毒性作用不受这种递送机制的阻碍。